SOD1 and amyotrophic lateral sclerosis: Based on these results, the FDA approved tofersen in April 2023 for the treatment of patients with amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene, followed by the EMA’s Committee for Human Medicines (CHMP) approval in February 2024.